Protein,DNA,InSiGHT Classification,French Classification,Tumor and age (years),MSI,IHC and/or other somatic data,Amsterdam or Bethesda criteria,Cancer and age (years) in relatives,Allele frequency (%),CADD score,Previous functional tests,MT assay result
L85P,254T>C,/,3*,CRC 49,YES,MLH1+ PMS2-,/,/,/,28.3,/,77.12% Potentially damaging
S106R,318C>A,3,3,/,YES,MLH1+ MSH2+ MSH6+ PMS2+,/,/,/,33,/,84.96% Damaging
T116K,347C>A,3,3,CRC 28,/,/,/,mat uncle: CRC 58,/,34,/,44.83% Neutral
Y126N,376T>A,3,3,LGD Ad 30 BC 73,/,/,/,non carrier sister: CRC 74; several BC in family,0.0074,31,/,51.99% Neutral
A160V,479C>T,3,/,CRC 68,YES,MLH1-,Amsterdam I,/,0.014,23,102% repair activity in vitro; dominant mutator effect; expression >75% in transfected HCT116 cells,27.69% Neutral
A160V,479C>T,3,/,BC,/,/,/,No CRC,0.014,23,102% repair activity in vitro; dominant mutator effect; expression >75% in transfected HCT116 cells,27.69% Neutral
V179D,536T>A,/,3*,CRC 59,/,/,/,Mother: CRC 65; mat aunt: GC 61; father: PrC PC 79; pat uncle: HCC; pat uncle's son: MSTO (asbestos),/,33,/,61.88% Potentially neutral
N215S,644A>G,3,3,Spo CRC <50,YES,/,/,/,0.0016,26.4,/,46.73% Neutral
G244V,731G>T,3,3,/,/,MLH1-,Bethesda,/,/,27.4,24% repair activity in vitro; No dominant mutator effect; expression >75% in transfected HCT116 cells,101.24% Damaging
G244V,731G>T,3,3,Spo CRC,YES,/,/,/,/,27.4,24% repair activity in vitro; No dominant mutator effect; expression >75% in transfected HCT116 cells,101.24% Damaging
G244V,731G>T,3,3,/,YES,MLH1+ MSH2+ MSH6+ PMS2-,/,/,/,27.4,24% repair activity in vitro; No dominant mutator effect; expression >75% in transfected HCT116 cells,101.24% Damaging
G244V,731G>T,3,3,/,YES,MLH1-,Amsterdam I,Non-carrier: CRC 60; asymptomatic carrier 80,/,27.4,24% repair activity in vitro; No dominant mutator effect; expression >75% in transfected HCT116 cells,101.24% Damaging
G244V,731G>T,3,3,/,YES,MLH1+ MSH2+ MSH6+ PMS2-,/,Carrier paternal uncle; paternal aunt asymptomatic carrier 65,/,27.4,24% repair activity in vitro; No dominant mutator effect; expression >75% in transfected HCT116 cells,101.24% Damaging
L260F,778C>T,3,3,CRC 41,/,MLH1+ PMS2+,Amsterdam II,Tested individuals: CCR 36; PrC 68; Untested individuals: CCR 34; CCR 45; CCR 55; CCR 45; EC 49; GC 58,/,32,/,76.37% Potentially damaging
L260F,778C>T,3,3,/,YES,MLH1-,/,/,/,32,/,76.37% Potentially damaging
H264Y,790C>T,3,3,CRC 30,YES,/,/,/,0.00087,32,/,63.65% Potentially neutral
E319K,955G>A,3,3,BC 45,/,MLH1+ MSH2+ MSH6+ PMS2+,/,Mother: BC 40; mat aunt: BC 40; mat aunt's daughter:BC 40,0.0082,35,/,32.28% Neutral
N338S,1013A>G,3,3,CRC 38,/,/,Bethesda,Father: lymphoma ; uncle: CRC,0.0058,15.9,/,44.57% Neutral
N338S,1013A>G,3,3,CRC 33,YES,MLH1- PMS2-,Bethesda,Untested individuals: skin; CCR 80; PrC 80; skin; CCR 50,0.0058,15.9,/,44.57% Neutral
G454R,1360G>C,3,1,/,NO,/,/,/,0.015,0.5,/,38.42% Neutral
G454R,1360G>C,3,1,/,/,MLH1+ MSH2-,/,/,0.015,0.5,/,38.42% Neutral
G454R,1360G>C,3,1,Ad,/,/,Bethesda,One unaffected carrier; Untested individuals: CRC 39; EC 42,0.015,0.5,/,38.42% Neutral
R474Q,1421G>A,3,1,/,/,/,/,/,0.00082,23.9,102% repair activity in vitro ; dominant mutator effect; expression >75% in transfected HCT116 cells,35.77% Neutral
R474W,1420C>T,3,/,/,/,/,/,/,0.0016,27.8,/,29.17% Neutral
R474G,1420C>G,/,3*,/,/,/,/,/,0.0082,23.5,/,28.28% Neutral
E523D,1569G>T,3,/,/,/,/,/,/,/,13.2,96% repair activity in vitro;dominant mutator effect; expression>75% in transfected HCT116 cells,49.04% Neutral
A539D,1616C>A,3,3,CRC <50,/,/,/,2 affected carriers in the family,/,25.7,/,98.51% Damaging
I565T,1694T>C,/,3*,/,/,/,/,/,/,26.9,/,45.13% Neutral
L582F,1744C>T,3,3,CRC 37,YES,MLH1- MSH2+ MSH6+ PMS2- No MLH1 methylation,Bethesda,/,/,28,30% repair activity in vitro; nuclear localization in murine NIH-3T3; defective PMS2 interaction,75.67% Potentially damaging
L582F,1744C>T,3,3,CRC 52,YES,MLH1-,/,/,/,28,30% repair activity in vitro; nuclear localization in murine NIH-3T3; defective PMS2 interaction,75.67% Potentially damaging
A586D,1757C>A,3,3,/,/,/,Amsterdam II,/,/,32,/,87.77% Damaging
K618E,1852A>G,3,3,/,/,/,Amsterdam II,/,0.34,27.8,/,50% Neutral
L622P,1865T>C,3,/,BC 38 CRC 48,YES,MLH1- PMS2-,Bethesda II,Untested individuals: GC 70; bladder; unknown cancer,/,29.2,/,75.68% Potentially damaging
L622P,1865T>C,3,/,CRC 43,YES,MLH1- PMS2-,Amsterdam II,Untested individuals with CRC: 31; 49; 69; 78; unknown,/,29.2,/,75.68% Potentially damaging
L622P,1865T>C,3,/,CRC 48 52 melanoma 54 GC 63,YES,MLH1- PMS2-,/,Brother: leukemia 51; sister: melanoma 40; pat uncle: CRC <60; pat grand-father: CRC <49,/,29.2,/,75.68% Potentially damaging
L622P,1865T>C,3,/,CRC 37,YES,MLH1- PMS2- No MLH1 methylation,/,Mother: CRC 45,/,29.2,/,75.68% Potentially damaging
P640L,1919C>T,3,5,/,YES,MLH1- PMS2-,Amsterdam I,/,/,34,No dominant mutator effect no interaction with PSM2 reduced MLH1 expression (in human transfected cells and in yeast cells),102.05% Damaging
P640L,1919C>T,3,5,EC 36 DC 48 CRC 56 UC 64,/,/,Amsterdam I,Father: CRC 38; pat uncle and grandfather: CRC,/,34,No dominant mutator effect no interaction with PSM2 reduced MLH1 expression (in human transfected cells and in yeast cells),102.05% Damaging
P640L,1919C>T,3,5,CRC 31,/,MLH1- PMS2-,Bethesda,Untested individuals: CRC 29; GC 55; CRC 81,/,34,No dominant mutator effect no interaction with PSM2 reduced MLH1 expression (in human transfected cells and in yeast cells),102.05% Damaging
P640L,1919C>T,3,5,CRC 48 55,YES,MLH1-,Bethesda,Untested relatives: EC; CRC; unknown,/,34,No dominant mutator effect no interaction with PSM2 reduced MLH1 expression (in human transfected cells and in yeast cells),102.05% Damaging
P640L,1919C>T,3,5,/,YES,/,Amsterdam I,1 affected carrier relative,/,34,No dominant mutator effect no interaction with PSM2 reduced MLH1 expression (in human transfected cells and in yeast cells),102.05% Damaging
W666R,1996T>C,3,3,/,/,/,/,/,/,26.2,/,88.21% Damaging
